Q2
KMB — Q2 2026 Financial Report Analysis
Kimberly-Clark's Q2 2026 sales rose 0.6% to $4.19B on currency alone and tariff refunds lifted adjusted EPS 10.4%, but Kenvue deal costs and tax charges tied to the tissue joint venture cut diluted EPS 32% to $1.04.